Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection

被引：19

作者：

Lin, Yen-Po ^{[1
]}

Lin, Shu-Hsien ^{[2
,3
]}

Wang, Chih-Chi ^{[3
,4
,5
]}

Lin, Chih-Che ^{[3
,4
,5
]}

Chen, Ding-Wei ^{[3
,5
,6
]}

Chuang, Ching-Hui ^{[7
]}

Huang, Pao-Yuan ^{[2
,3
]}

Hung, Chao-Hung ^{[2
,3
]}

Yang, Shih-Yu ^{[2
,3
]}

Cho, Wei-Ru ^{[2
,3
]}

Chen, Yu-Syuan ^{[1
]}

Tsai, Ming-Chao ^{[1
,8
]}

机构：

[1] Chung Shan Med Univ, Sch Med, Taichung 40201, Taiwan

[2] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Kaohsiung 83301, Taiwan

[3] Chang Gung Univ, Coll Med, Kaohsiung 83301, Taiwan

[4] Kaohsiung Chang Gung Mem Hosp, Liver Transplantat Ctr, Kaohsiung 83301, Taiwan

[5] Kaohsiung Chang Gung Mem Hosp, Dept Surg, Kaohsiung 83301, Taiwan

[6] Kaohsiung Chang Gung Mem Hosp, Ctr Translat Res Biomed Sci, Liver Transplantat Program, Kaohsiung 83301, Taiwan

[7] Meiho Univ, Dept Nursing, Pingtung 91202, Taiwan

[8] Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, Kaohsiung 83301, Taiwan

来源：

JOURNAL OF PERSONALIZED MEDICINE | 2021年 / 11卷 / 08期

关键词：

metabolic-associated fatty liver disease (MAFLD); non-alcoholic fatty liver disease (NAFLD); chronic hepatitis B; hepato-cellular carcinoma; lean MAFLD; FATTY LIVER-DISEASE; LEAN PATIENTS; RISK-FACTORS; RECURRENCE; PATTERNS; CANCER;

D O I：

10.3390/jpm11080684

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Backgrounds and Aim: Metabolic-associated fatty liver dis-ease (MAFLD) is a novel term proposed in 2020 to avoid the exclusion of certain subpopulations, though the application of this term in the real world is very limited. Here, we aimed to evaluate the impact of MAFLD on hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) after curative resection. Methods: Patients with chronic hepatitis B (CHB)-related HCC who received hepatectomy between January 2010 and December 2019 were consecutively selected. The association between histologically proven concurrent MAFLD and clinical outcomes were retrospectively analyzed. Results: Among the 812 eligible patients with CHB-related HCC, 369 (45.4%) were diagnosed with concurrent MAFLD. After a mean follow-up of 65 months, 303 patients (37.3%) developed HCC recurrence, 111 (13.7%) died, and 12 (1.5%) received liver transplantation. Although no differences in the incidences of HCC recurrence (HR: 0.902, 95% CI: 0.719-1.131, p = 0.370) and death or liver transplantation (HR: 0.743, 95% CI: 0.518-1.006, p = 0.107) were observed between patients with and without MAFLD in multivariate analysis, the patients with MAFLD tended to achieve better recurrent-free survival compared to patients without MAFLD. Notably, lean MAFLD (BMI < 23 kg/m(2)) was a relative risk factor for tumor recurrence (HR: 2.030, 95% CI: 1.117-3.690, p = 0.020) among patients with MAFLD. Conclusions: The overall prognosis in HBV-related early-stage HCC, in terms of HCC recurrence and death or liver transplantation, was not significantly different between patients with and without MAFLD. Among patients with MALFD, lean-MAFLD was a risk factor for HCC recurrence. Further studies are warranted to validate these results.

引用

页数：17